Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COCPNASDAQ:LPCNNASDAQ:MTCRNASDAQ:ONTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOCPCocrystal Pharma$1.68+1.8%$1.44$1.12▼$3.26$17.09M2.1327,716 shs12,518 shsLPCNLipocine$3.20-2.4%$3.25$2.68▼$11.79$17.12M1.5235,221 shs8,807 shsMTCRMetacrine$0.58$0.57$0.30▼$0.59$24.75M-0.73225,834 shs83,889 shsONTXOnconova Therapeutics$0.85$0.55▼$1.45$20.90M1.3896,681 shs1.28 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOCPCocrystal Pharma-2.94%+13.01%+3.12%-5.98%-26.67%LPCNLipocine-2.38%-8.38%-3.81%+6.84%-52.60%MTCRMetacrine0.00%0.00%0.00%0.00%0.00%ONTXOnconova Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOCPCocrystal Pharma2.6643 of 5 stars3.53.00.00.02.61.70.6LPCNLipocine2.5634 of 5 stars3.83.00.00.03.20.00.6MTCRMetacrineN/AN/AN/AN/AN/AN/AN/AN/AONTXOnconova TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOCPCocrystal Pharma 3.00Buy$7.00316.67% UpsideLPCNLipocine 3.50Strong Buy$9.00181.25% UpsideMTCRMetacrine 0.00N/AN/AN/AONTXOnconova Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest COCP, ONTX, MTCR, and LPCN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025LPCNLipocineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$8.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOCPCocrystal PharmaN/AN/AN/AN/A$2.59 per shareN/ALPCNLipocine$3.67M4.66N/AN/A$3.83 per share0.84MTCRMetacrineN/AN/AN/AN/A$1.36 per shareN/AONTXOnconova Therapeutics$230K0.00N/AN/A$1.35 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOCPCocrystal Pharma-$17.98M-$1.57N/AN/AN/AN/A-94.62%-78.24%8/13/2025 (Estimated)LPCNLipocine-$16.35M-$1.02N/A∞N/AN/A-19.17%-17.60%8/6/2025 (Estimated)MTCRMetacrine-$62.21M-$1.03N/A∞N/AN/A-84.88%-59.33%N/AONTXOnconova Therapeutics-$18.96M-$0.91N/AN/AN/A-8,930.97%-95.43%-61.19%N/ALatest COCP, ONTX, MTCR, and LPCN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025COCPCocrystal Pharma-$0.52-$0.23+$0.29-$0.23N/AN/A5/8/2025Q4 2024LPCNLipocine-$0.35-$0.35N/A-$0.35$0.35 million$0.09 million3/27/2025Q4 2024COCPCocrystal Pharma-$0.55-$0.32+$0.23-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOCPCocrystal PharmaN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/AMTCRMetacrineN/AN/AN/AN/AN/AONTXOnconova TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOCPCocrystal PharmaN/A7.327.32LPCNLipocineN/A12.9712.97MTCRMetacrine0.3412.1512.15ONTXOnconova TherapeuticsN/A2.792.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOCPCocrystal Pharma6.72%LPCNLipocine9.11%MTCRMetacrine37.72%ONTXOnconova Therapeutics7.95%Insider OwnershipCompanyInsider OwnershipCOCPCocrystal Pharma28.14%LPCNLipocine6.12%MTCRMetacrine13.80%ONTXOnconova Therapeutics3.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOCPCocrystal Pharma1010.17 million7.57 millionNot OptionableLPCNLipocine105.35 million5.02 millionNo DataMTCRMetacrine1042.57 million36.70 millionNot OptionableONTXOnconova Therapeutics1621.00 million20.31 millionOptionableCOCP, ONTX, MTCR, and LPCN HeadlinesRecent News About These CompaniesOnconova Therapeutics Regains Compliance with Nasdaq Continued Listing RequirementAugust 9, 2024 | br.advfn.comTRAW Traws Pharma, Inc.July 20, 2024 | seekingalpha.comOnconova and Trawsfynydd merge to form Traws PharmaApril 4, 2024 | uk.investing.comTraws Pharma Full Year 2023 Earnings: Beats ExpectationsApril 4, 2024 | finance.yahoo.comNewtown’s Onconova Therapeutics Secures $14 Million and New CEO in Merger with TrawsfynyddApril 3, 2024 | msn.comOnconova Acquires Trawsfynydd To Form Traws PharmaApril 2, 2024 | markets.businessinsider.comTraws Pharma Announces New Employee Inducement GrantsApril 2, 2024 | globenewswire.comOnconova to Unveil New Rigosertib Study Results at Cancer Research MeetingMarch 12, 2024 | msn.comAnalysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX) and Biogen (BIIB)March 11, 2024 | markets.businessinsider.comOnconova Therapeutics’ Rigosertib Poster Selected for AACR 2024March 8, 2024 | finance.yahoo.comOnconova Therapeutics' Rigosertib Poster Selected for AACR 2024March 8, 2024 | globenewswire.comOnconova Therapeutics Inc (ONTX)February 13, 2024 | investing.comOnconova Therapeutics, Inc. (ONTX)January 23, 2024 | finance.yahoo.comOnconova Therapeutics Stock (NASDAQ:ONTX) Dividends: History, Yield and DatesDecember 21, 2023 | benzinga.comOnconova stock falls 10% on preclinical data for lymphoma drugDecember 12, 2023 | msn.comOnconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell LymphomaDecember 12, 2023 | finance.yahoo.comOnconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’sDecember 8, 2023 | finance.yahoo.comOnconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity ConferenceNovember 28, 2023 | finance.yahoo.comOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Call TranscriptNovember 16, 2023 | finance.yahoo.comOnconova Therapeutics, Inc.: Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial ResultsNovember 16, 2023 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCOCP, ONTX, MTCR, and LPCN Company DescriptionsCocrystal Pharma NASDAQ:COCP$1.68 +0.03 (+2.06%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Lipocine NASDAQ:LPCN$3.20 -0.08 (-2.44%) Closing price 04:00 PM EasternExtended Trading$3.18 -0.03 (-0.78%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.Metacrine NASDAQ:MTCRMetacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Onconova Therapeutics NASDAQ:ONTXOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
